Company intelligence / Profile preview

Sunridge International

Fountain Hills, Arizona, United States

Ownership: Private
Development stage: Other

Overview

Pneumatic Trabeculoplasty (PNT) has been proven through studies completed over 10 years to be a safe and effective treatment with no adverse side effects for glaucoma and ocular hypertension[1]. The company received 2A approval for Europe after several years of successful clinical trials costing over $12 million[1].

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Exclusive distributors in EuropeBeijing Vision World Trading Co., Ltd. (China)New Amsterdam Marketing (India)

Beyond the preview

Go deeper on Sunridge International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sunridge International.

Explore the full profile